A
1.53
0.04 (2.68%)
| Previous Close | 1.49 |
| Open | 1.49 |
| Volume | 993,278 |
| Avg. Volume (3M) | 1,601,706 |
| Market Cap | 407,199,200 |
| Price / Sales | 4.50 |
| Price / Book | 3.83 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2026 |
| Operating Margin (TTM) | -726.31% |
| Diluted EPS (TTM) | -0.880 |
| Quarterly Revenue Growth (YOY) | -11.00% |
| Total Debt/Equity (MRQ) | 83.84% |
| Current Ratio (MRQ) | 9.24 |
| Operating Cash Flow (TTM) | -241.32 M |
| Levered Free Cash Flow (TTM) | -214.39 M |
| Return on Assets (TTM) | -20.27% |
| Return on Equity (TTM) | -49.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Autolus Therapeutics plc | Bearish | Bullish |
AIStockmoo Score
-1.4
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | -1.38 |
|
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 18.09% |
| % Held by Institutions | 90.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Syncona Portfolio Ltd | 31 Mar 2026 | 16,640,720 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |